Sometimes you realize that we are on the cusp of a structural change, a tipping point if you will. Given what we have witnessed over the past few weeks we sense that we have reached such a point when it comes to intensive and semi-intensive insulin management. The results from Abbott, Dexcom, Tandem, Insulet and even Medtronic have painted a graphic picture of the future.
We’re not sure when we said it, but it wasn’t that long ago that we stated it will soon be easier to be an insulin using patient then a non-insulin . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.